Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company OncoImmune Inc.
DescriptionRecombinant fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain
Molecular Target CD24
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today